ttorney's Docket No. PP01543.201 (035784/208771)

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Whitehouse

Confirmation No.: 7656

Appl. No.: 09/771,302

Group Art Unit: 1647

Deberry, Regina M.

Filed:

January 26, 2001

Examiner:

For:

ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2 AND METHOD OF

USE

February 11, 2003

TECH CENTER 1600/2900

BOX NON-FEE AMENDMENT Commissioner for Patents Washington, DC 20231

AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111

Sir:

Responsive to the Office Action mailed November 15, 2002, reexamination and reconsideration of the above-identified application are respectfully requested in view of the following amendments and remarks. The Examiner is respectfully requested to enter the following amendments.

In the Specification:

Please amend the paragraph, beginning on page 8, line 27, and continuing through page 9, line 15, to read as follows:

As part of this study, MRI was also performed on 33 human patients diagnosed with CAD to assess the effect of administering a single unit dose of rFGF-2 on their cardiac ejection fraction, regional myocardial function and perfusion (delayed arrival zone). Specifically, the patients were administered a single unit dose of 0.33 mg/kg to 48 mg/kg IC or 18 mg/kg to 36 mg/kg IV of rFGF-2 of SEQ ID NO: 2. When the 33 human CAD patients were assessed by resting cardiac magnetic resonance imaging (MRI) at baseline (i.e., prior to treatment), and 1, 2 and 6 months after treatment with a single unit dose of rFGF-2 of the invention by IC or IV routes, the patients exhibited a highly statistically significant response to the method of treatment as objectively measured by increased target wall thickening, target wall motion, and target area